Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier ...

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Middle East

◆ Source

Read at ir.ocugen.com →

◆ Verified

Fusion42 · 15 October 2026 · Fusion42 review

Ocugen has signed a licensing agreement with Roots Pharmaceutical to commercialise its gene therapy OCU400 for retinitis pigmentosa across the Middle East and North Africa. The deal includes upfront and milestone payments, royalties, and positions Ocugen to expand access in a region with high disease prevalence.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your gene therapy can now reach patients in the Middle East through a partner with regional reach. This deal opens a pathway to commercial scale in a high-need market where competition is minimal.

◆ Coverage

1 source · 14 Oct 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyretinitis-pigmentosamiddle-eastlicense-agreementrare-diseasecommercial-expansion